Rivaroxaban (Xarelto) Table    body {font-family: 'Open Sans', sans-serif;}

### Rivaroxaban (Xarelto) Table

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Xarelto at doses: | Minimal Time between  
last dose and block | Can it be given with  
epidural catheter in place? | When to restart Xarelto  
after catheter removal |
| --- | --- | --- | --- |
| 10mg PO QDay  
(low dose) | ASRA: 72 hours, if earlier, verify anti-factor  
Xa activity.  
  
Other source:  
48 hours: CrCl â‰¥ 50 ml/min  
72 hours: CrCl 30-50 ml/min  
CrCl < 30 ml/min:  
Call Hematology | Avoid with indwelling catheter  
  
If indwelling catheter is in:  
Hold for 22-26 hours or  
verify anti-factor  
Xa activity. | 6 hours |
| 15-20mg PO  
Q Day or BID | ASRA: 72 hours, if earlier, verify anti-factor  
Xa activity.  
  
Other source:  
48 hours: CrCl >50 ml/min CrCl < 50 ml/min:  
Call Hematology | Avoid with indwelling catheter  
  
If indwelling catheter is in:  
Hold for 22-26 hours or  
verify anti-factor Xa activity. | 6 hours |

  
**Deep plexus and peripheral blocks:** Same recommendations as neuraxial.**Superficial peripheral blocks:** Based on vascularity, site compressibility and available management if bleeding occurred.**Other source:  
Creatinine Clearance > 50 ml/min:** Hold drug x 1 day prior to minor surgery - Hold drug x 2  
days prior to major surgery  
  
**Creatinine Clearance 30-50 ml/min:** Hold drug x 1-2 days prior to minor surgery  
Hold drug x 3-4 days prior to major surgery  
  
**Creatinine Clearance < 30 ml/min:** Call Hematology  
  
**Labs:  
**Anti-Xa chromogenic assay  
Always refer to the latest ASRA (American Society of Regional Anesthesia and Pain) Recommendations  
https://www.asra.com/advisory-guidelines  
  
ASRA Assistance:  
Toll free in US: 855-795-ASRA (2772)  
412-471-2718  
asraassistant@asra.com  
  

Other source  
MANAGEMENT OF ANTITHROMBOTIC THERAPY  
FOR NEURAXIAL AND PERIPHERAL NERVE PROCEDURES, 2018  
https://depts.washington.edu/anticoag/home/sites/default/files/Management%20of%20Antithrombotic%20Therapy%20for%20Neuraxial%20and%20Peripheral%20Nerve%20Procedures.pdf